Antibody that keeps T cells out of the brain preserved memory tissue in tauopathy mice
Washington University researchers report that a CXCR3-blocking antibody halved brain T cells and spared 40% more memory-region tissue in tauopathy mice. Tau levels never fell, evidence the immune reaction to tau does much of the killing.
The Scientist · Science desk
What happened
- Treated mice performed significantly better on a memory test than untreated animals that carried the same load of tau tangles.
- The antibody accumulated only at the structural borders of the brain and did not enter the deep tissue, so it acted from the periphery.
- A related study the same group published in Nature Neuroscience on September 3 traced the invading T cells back to activation in lymph nodes outside the brain.
- The two approved Alzheimer's drugs, lecanemab and donanemab, target amyloid and have not been shown to keep brain cells from dying.
Why it matters
- What's now possible capability A therapy built on this route would not have to be engineered to cross the blood-brain barrier, the obstacle that stops most nervous-system drugs before they reach the tissue.
- Who has to decide decision Because drugs that manipulate T cells are already approved for other diseases, those existing agents become candidates to test against tauopathy rather than compounds built from scratch.
- What it limits constraint The tau protein was left untouched, so the approach blunts the immune damage without removing what provokes it; whether the residual tau harms the brain over a longer course is untested.
- Who's exposed exposure For primary tauopathies, where amyloid never appears and the approved anti-amyloid drugs do nothing, an immune-entry route opens a strategy those patients did not have.
Next story · Science · yesterday
Genome-wide CRISPR screen implicates Wnt signaling in APOE4's myelin damageConfirmed2 publishers
T cells find their way by following chemical trails called chemokines. Holtzman's group had found that one of those trails, a chemokine called CXCL10, runs high both in the tau mouse model they used and in people with Alzheimer's disease [1]. Activated T cells carry a surface receptor, CXCR3, that reads the CXCL10 signal and follows it into brain tissue [2]. When the team bred mice without either CXCL10 or CXCR3, the cells could not get into the brain even after the researchers set off inflammation on purpose [3]. The antibody blocks that same receptor from the blood side.
The antibody built up at the structural borders of the brain and did not reach the deep tissue [4]. "One of the issues in developing treatments for neurological diseases is that you need to engineer your treatment so that it gets into the brain and past the blood-brain barrier, but we might not actually need to get the drugs into the central nervous system to mitigate neurodegeneration," Holtzman said [5].
The tissue survived without any drop in tau. Levels of both soluble and insoluble tau were the same in treated and untreated animals [6]. In the paper, published in the journal Neuron [16], the authors wrote that the CXCR3 axis is "a critical target that, when blocked, mitigates CD4+ and CD8+ T cell infiltration and confers neuroprotection in a model of tau-mediated neurodegeneration in vivo without influencing levels of soluble or insoluble tau" [19].
The study does not settle whether any of this carries to people. The animals were young and carried Alzheimer's-like tau buildup, and the antibody went in every five days for three and a half months [7]. The reports describe the memory result only as significantly better than untreated controls; they do not put a number on it [8]. And because the protein itself was left in place, the work shows that blocking immune entry protects tissue, not that the tau is harmless once the T cells are held back.
"In tauopathies, including Alzheimer's disease, there's no treatment right now that actually decreases neurodegeneration," Holtzman said. "If we can show that we're really decreasing brain cell death, it's certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases." [15]
What to watch
- Whether the antibody protects older mice or animals that already carry advanced tau tangles, not only young mice dosed early.
- Whether an existing, approved T-cell drug can reproduce the effect and move into human trials for tauopathy.
- Whether human tauopathy patients show the same CXCL10-to-CXCR3 T-cell entry route seen in the mouse brains.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+30
- Incentives40
- Confidence60
Perspective Coverage
3 publishers- Builder
- Builder 53%
- Operator
- Operator 25%
- Investor
- Investor 22%
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
The chemokine CXCL10 is elevated both in the tau-model mice used in the study and in human Alzheimer's patients.
- [2]
Activated T cells carry a surface receptor called CXCR3 that tracks the CXCL10 trail into neural tissue.
- [3]
In mice engineered to lack either CXCL10 or the CXCR3 receptor, T cells failed to breach the brain even when acute inflammation was artificially triggered.
- [4]
The CXCR3 antibody accumulated only at the structural borders of the brain and did not enter the deep parenchyma.
- [5]
David Holtzman said: "One of the issues in developing treatments for neurological diseases is that you need to engineer your treatment so that it gets into the brain and past the blood-brain barrier, but we might not actually need to get the drugs into the central nervous system to mitigate neurodegeneration."
- [6]
The levels of soluble and insoluble tau in the treated mice did not change relative to untreated mice.
- [7]
The team administered an antibody targeting CXCR3 every five days for three and a half months to young mice exhibiting tau buildup.
- [8]
Treated mice performed significantly better on memory tests than untreated controls, described only as significantly better without a quantified effect size.
- [9]
Existing Alzheimer's drugs lecanemab and donanemab target amyloid plaques, can modestly slow cognitive decline, and have not been shown to halt ongoing brain-cell loss.
- [10]
The anti-amyloid drugs offer no clinical benefit for primary tauopathies, where tau accumulates in the total absence of amyloid.
- [11]
In a related study published in Nature Neuroscience on September 3, the group showed that the T cells contributing to brain damage are activated in lymph nodes outside the brain before entering the nervous system.
- [12]
Injecting the CXCR3 antibody over several months reduced the number of T cells in the brain by about half.
- [13]
Treated mice kept roughly 40% more tissue in the memory centers of the brain than untreated mice.
- [14]
Researchers at Washington University School of Medicine in St. Louis developed the antibody-based approach; David M. Holtzman is senior author of the study.
- [15]
Holtzman said: "In tauopathies, including Alzheimer's disease, there's no treatment right now that actually decreases neurodegeneration. If we can show that we're really decreasing brain cell death, it's certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases."
- [16]
The study was published in the journal Neuron under the title "Peripheral CXCR3 blockade mitigates T cell infiltration and neurodegeneration in a mouse model of tauopathy."
- [17]
Holtzman said: "There are lots of ways to manipulate T cells that have been studied extensively and that are approved treatments for other diseases, but many haven't yet been explored for neurodegenerative diseases."
- [18]
A growing body of evidence indicates that tau aggregates may not directly kill brain cells; rather, the immune system's inflammatory reaction to tau drives much of the damage.
- [19]
The authors concluded that their study "defines the CXCR3 axis as a critical target that, when blocked, mitigates CD4+ and CD8+ T cell infiltration and confers neuroprotection in a model of tau-mediated neurodegeneration in vivo without influencing levels of soluble or insoluble tau."
Sources
2 independent publishers whose own reporting we read for this story.
- genengnews.comAntibody Blocks T Cell Infiltration and Limits Neurodegeneration in Alzheimer’s Mice
1 article · September 28, 2026
- neurosciencenews.comBlocking Immune Cells Protects Memory and Brain Tissue in Alzheimer’s
1 article · September 28, 2026
- sciencedaily.comScientists found a surprising driver of Alzheimer’s outside the brain
1 article · September 27, 2026
Topics and entities
Entities
- Neuron
- WashU Medicine
- David M. Holtzman